Patent · US Active

Vidofludimus for use in the treatment or prevention of viral diseases

US12167994B2 · kind B2 · utility

0Cited by

6References

19Claims

0Family size

Assignee

IMMUNIC AG · DE

Inventors

Manfred GRÖPPEL · Erlangen, DE
Daniel VITT · Germering, DE
Hella KOHLHOF · Munich, DE
Andreas Muhler · Oderberg, DE

Key dates

Filing date	Jul 1, 2022
Grant date	Dec 17, 2024
Priority date	—
Expiry date	Dec 30, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a compound according to Formula (I) or a salt, solvate and/or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.